This page features the latest news about the Revolution Med stock. Revolution Medicines executive sells over $58k in company stock In a recent transaction, Jeff Cislini, the General Counsel of ...

Revolution Medicines (RVMD) announced preliminary safety and antitumor data for RMC-9805, its RAS G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging ...